Your browser doesn't support javascript.
loading
Long-term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study.
Tchang, Beverly G; Aras, Mohini; Wu, Alan; Aronne, Louis J; Shukla, Alpana P.
Afiliación
  • Tchang BG; Department of Medicine Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center Weill Cornell Medicine New York New York USA.
  • Aras M; Department of Medicine Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center Weill Cornell Medicine New York New York USA.
  • Wu A; Division of Biostatistics and Epidemiology Department of Healthcare Policy & Research Weill Cornell Medicine New York New York USA.
  • Aronne LJ; Department of Medicine Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center Weill Cornell Medicine New York New York USA.
  • Shukla AP; Department of Medicine Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center Weill Cornell Medicine New York New York USA.
Obes Sci Pract ; 8(3): 320-327, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35664243
Objective: To determine the association of anti-obesity medications (AOMs) with weight loss maintenance over 2 years. Methods: This is a retrospective observational cohort study of adults treated for obesity between 1 April 2014 and 1 April 2016 at a tertiary academic weight management center and who completed 2 years of follow-up. Main outcome measures were mean percent weight loss, percent of individuals who achieved clinically significant long-term weight loss (≥5% weight loss over 2 years), and long-term weight loss maintenance (achievement of ≥5% weight loss at 1 year and maintenance of the ≥5% reduction for the second year). Results: Of the 1566 new patients, 421 completed 1- and 2-year follow-up appointments. Patients were mostly female and on average 51 years old; they weighed 100.1 kg and had a BMI of 35.8 kg/m2 at initial visit. Mean weight losses at 1 and 2 years were 10.1% and 10.2%, respectively. The proportion of patients who experienced ≥5% weight loss was 75.5% at 1 year and 72.9% at 2 years. Long-term weight loss maintenance was achieved by 65.3% of patients. Almost all (96.2%) were on ≥1 AOM at 2 years, with metformin, phentermine, and topiramate among the most prescribed. AOM usage and older age demonstrated trends toward predicting weight loss maintenance over 2 years. Conclusions: Long-term weight loss maintenance was observed among adults with medically managed obesity who completed 2 years of follow-up.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Obes Sci Pract Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Obes Sci Pract Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos